- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Genentech and UC Settle Patent Battle
16 November 1999 6:00 pm
One of the longest patent fights in biotech history may at last be over. Today, the Los Angeles Times reported that Genentech Inc. of South San Francisco had agreed to pay the University of California (UC) $200 million for having infringed on UC's patent on a genetically engineered human growth hormone.
A trial on the decade-old infringement case ended with a hung jury in June (Science, 11 June, p. 1752). Now, a scheduled January retrial appears to have been averted.
According to the Times, nearly half of the settlement will be split among the five scientists named as co-discoverers on the patent, and the remainder will go to UC San Francisco, with $50 million earmarked to fund a new research building. Today, UC and Genentech were staying silent on the deal until the UC Regents had a chance to review it at a meeting earlier this week.